Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 16,043

Document Document Title
WO/2019/054944A1
The present invention relates to compounds of general Formula (I), and/or tautomers, enantiomers, solvates, hydrates, and pharmaceutically acceptable salts thereof. The present invention also relates to compounds of Formula (I) for use i...  
WO/2019/055540A1
A compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.  
WO/2019/054430A1
The purpose of the present invention is to provide a compound having an anti-inflammatory action, a pharmacologically acceptable salt thereof, etc. A solving means of the present invention is a compound of general formula (1) or a pharma...  
WO/2019/053634A1
The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharma...  
WO/2019/051199A1
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...  
WO/2019/047826A1
An aromatic derivative as represented by formula (I), a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising same, a preparation method therefor, and uses of the aromatic derivative and the pharmaceutically...  
WO/2019/051396A1
Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity: formula (I), wherein A is N or CR...  
WO/2019/045035A1
The present invention relates to biaryloxy derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage ...  
WO/2019/043372A1
There are described compounds of formula (I) in which X, R1, R2 and n are each as herein defined; and their use as a medicament in the treatment of conditions involving abnormal activation and/or malfunction of the hedgehog pathway, such...  
WO/2019/044266A1
A method for producing a pyrazole-4-carboxamide derivative by subjecting a pyrazole-4-carboxylic acid ester and an amine to an aminolysis reaction in a solvent in the presence of a base, the method being characterized in that the reactio...  
WO/2019/046467A1
The invention provides compounds of formula (I): and salts thereof wherein R1-R5 have any of the meanings described in the specification. The compounds are useful for treating bacterial infections (e.g. tuberculosis).  
WO/2019/017857A3
The invention relates to synthesis of potential anticancer effective 4-(3-(2-arylidenhydrazine- 1-carbonyl)-5-(aryl)-1H-pyrazole-1-yl) benzensulfonamide compounds, enlightenment of their structures and their cytotoxic activities.  
WO/2019/041340A1
A compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described.  
WO/2019/039290A1
Provided are: an actinic ray-sensitive or radiation-sensitive resin composition that has excellent resolution, exposure latitude, and pattern shape properties; and a resist film, a pattern-forming method, a method for producing an electr...  
WO/2019/040319A1
Provided are methods and compositions for prolonging survival and/or reducing or inhibiting tumor growth in a cancer subject receiving a regimen of one or more chemotherapeutic agents, an inhibitor of soluble epoxide hydrolase (sEHi) and...  
WO/2019/034686A1
The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; ...  
WO/2019/033590A1
Disclosed are a substituted benzoyl cyclohexanedione compound or a tautomer and salt thereof, a preparation method therefor, a herbicidal composition and the use. The substituted benzoyl cyclohexanedione compound or a tautomer and salt t...  
WO/2019/034690A1
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with a nitrogen-containing group ...  
WO/2019/034688A1
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl group substituted with an amide-containing group. The present invention further relates to salts, solvates and prodrugs of such compo...  
WO/2019/034692A1
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of...  
WO/2019/033068A1
Disclosed herein are methods of using a 5-HT2A serotonin receptor inverse agonist for the prophylaxis and/or treatment of psychosis or psychotic symptoms in an individual comprising administering to said individual in need thereof a ther...  
WO/2019/030358A1
Compounds of formula (I) as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and con...  
WO/2019/028689A1
The present invention relates to a crystalline form of N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)prop-2- yl)-5-(1-hydroxylethyl)-1H-pyrazole-3-carboxamide (namely, ODM-201). The ODM-201 crystalline form of the present inventio...  
WO/2019/025467A1
The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful fo...  
WO/2019/023147A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, c...  
WO/2019/022179A1
To provide a heterocyclic compound which can exhibit an antagonistic action to NR2B subunit-containing NMDA receptors and, therefore, is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder,...  
WO/2019/023145A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, ...  
WO/2019/020726A1
The invention discloses a method for preparation of alkylated, fluoro alkylated, chloro alkylated and fluorochloro alkylated compounds by a heterogeneous Co-catalysed alkylation or fluoro, chloro and fluorochloro alkylation with alkyl ha...  
WO/2019/023553A1
The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to ...  
WO/2019/016069A1
The invention relates to substituted 5-(Het-)arylpyrazolamides of general formula (I) and to the their use as herbicides, in particular for controlling weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators...  
WO/2019/018536A1
Provided here are compositions containing a conjugate of a label, a chelator, and a cannabinoid analog and methods for diagnosing, treating, or monitoring the progression of a cancer or a neurologic disorder using these compositions. Als...  
WO/2019/018853A1
The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.  
WO/2019/010715A1
The present invention relates to the technical field of herbicide crystallisation processes, and relates in particular to a dicarfentrazone-ethyl crystalline form E, and a preparation method therefor and a use thereof. The X-ray powder d...  
WO/2019/010717A1
The present invention relates to the technical field of herbicide crystallisation processes, and relates in particular to a dicarfentrazone-ethyl crystalline form C, and a preparation method therefor and a use thereof. The X-ray powder d...  
WO/2019/010718A1
The present invention relates to the technical field of herbicide crystallisation processes, and relates in particular to a dicarfentrazone-ethyl crystalline form B, and a preparation method therefor and a use thereof. The X-ray powder d...  
WO/2019/010716A1
The present invention relates to a dicarfentrazone-ethyl crystalline form D, and a preparation method therefor and a use thereof. The X-ray powder diffraction pattern of the dicarfentrazone-ethyl crystalline form D has characteristic pea...  
WO/2019/014308A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2019/009412A1
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...  
WO/2019/001361A1
A piperic acid derivative and preparation and an application thereof. The structure of the derivative is as shown in general formula I. The compound of general formula I has excellent pesticidal, miticidal, and bactericidal activities an...  
WO/2019/004584A1
The present invention relates to a novel compound and an organic electroluminescent device comprising the same. The compound according to the present invention is used as an organic layer of an organic electroluminescent device and, pref...  
WO/2019/000237A1
Provided are pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. Provided is also use of the compounds described herein in the potential treatment or prevention of neurological and...  
WO/2019/005589A1
The present invention is directed to 5-(pyridine-3-yl)oxaxole compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the ...  
WO/2019/001379A1
The present invention relates to an indazole compound for use in inhibiting kinase activity, and relates to a preparation and use thereof. Specifically disclosed in the present invention is an indazole compound represented by formula (I)...  
WO/2019/000236A1
Disclosed are pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor, uses of the compounds described herein in the potential treatment of prevention of neurological and psychiatric di...  
WO/2019/005587A1
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the pot...  
WO/2019/005588A1
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the pot...  
WO/2018/235966A1
The present invention provides a compound which has an excellent inhibitory activity on histone acetyltransferase of EP300 and/or CREBBP, or a pharmacologically acceptable salt of the compound. A compound represented by formula (1) or a ...  
WO/2018/230528A1
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...  
WO/2018/225018A1
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...  
WO/2018/217631A1
The present disclosure provides compositions including a α4β2 nAChR antagonist, pharmaceutical compositions including a α4β2 nAChR antagonist, methods of making the compositions or pharmaceutical compositions, methods of treatment of...  

Matches 1 - 50 out of 16,043